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Mast cells (MC) are important cellular components of
the immune network in diverse organs. The skin MC
has likewise been implicated in IgE- and complement-
mediated cutaneous reactions. Such reactions supposedly
involve specific cell surface membrane receptors. In this
study, the cell surface marker profile of human skin MC
was established using monoclonal antibodies (MoAb)
against defined CD antigens. MC were isolated from
juvenile foreskin (n J 55) and adult mammary skin
(n J 5). The reactivity of MC with MoAb was assessed by
a combined toluidine blue/immunofluorescence staining
technique. Confirming our previous analyses on lung
MC, foreskin MC reacted with MoAb against CD9, CD29,
CD33, CD43, CD44, CD45, CD46, CD51, CD54, CD55,
CD58, CD59, CD61, and CD117 (c-kit). Foreskin MC
were also recognized by MoAb to CD47, CD48, CD49d,
CD53, CD60, CD63, CD81, CD82, CD84, CD87, CD92,
Mast cells (MC) are proinflammatory effector cells ofthe immune system (Schwartz, 1985; Galli, 1993).These cells produce several vasoactive and otherbiologically relevant molecules (Lewis and Austen,1981; Serafin and Austen, 1987; Gordon et al,
1990). Under certain conditions and in response to diverse stimuli,
MC release their products and thereby can participate in a number of
pathophysiologic processes (Siraganian, 1985; Galli, 1990, 1993;
Dvorak, 1991; Walsh et al, 1991).
The various functional properties of MC are associated with expres-
sion of distinct cell surface membrane receptors (Valent and Bettelheim,
1992). The mast cell growth factor receptor (5 c-kit) is expressed on
mature MC as well as on MC progenitors (Galli, 1993; Valent, 1994;
Rodewald et al, 1996). The ligand of c-kit, mast cell growth factor
(MGF), also termed stem cell factor (SCF), induces differentiation,
mediator secretion, and chemotaxis in human (and murine) MC (Irani
et al, 1992; Bischoff and Dahinden, 1992; Valent et al, 1992; Mitsui
et al, 1993; Nilsson et al, 1994). The mast cell high affinity receptor
for IgE (immunoglobulin E) is involved in allergen-induced mediator
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CD97, CD98, and CD99. Recently clustered CD antigens
detectable on foreskin MC were CD147 (neurothelin),
CD149 (MEM133), CD151 (PETA-3), and CD157 (BST-
1). In contrast to lung MC and MC from adult skin,
foreskin MC were found to express CD88 (C5aR). Also,
cutaneous MC (from both juvenile foreskin and adult
mammary skin), but not lung MC, were found to bind
the CD32 MoAb IV.3, 2E1, and FLI8.26 (FcgRII). The
CD50 antigen (ICAM-3) was detectable on lung MC, but
not on foreskin MC or MC of adult mammary skin. In
summary, our data show that cutaneous MC and lung
MC express an almost identical phenotype; however, in
contrast to lung MC, cutaneous MC appear to express
substantial amounts of CD32 and to lack CD50. In
addition, foreskin MC, unlike MC from adult skin or
lung, express CD88. Key words: C5aR/c-kit/cutaneous mast
cells/histamine/IgER. J Invest Dermatol 111:689–695, 1998
release (Ishizaka and Ishizaka, 1984). MC also express a number of
adhesion receptors and recognition molecules, as well as cell surface
receptors for complement activation products (Valent and
Bettelheim, 1992).
During the past few decades substantial evidence for the existence
of subpopulations of MC has been accumulated (Befus et al, 1985;
Irani et al, 1986; Enerba¨ck, 1987; Kitamura, 1989). Human MC can
be subclassified based on expression of the two proteolytic MC
enzymes, tryptase and chymase (Irani et al, 1986), expression of cell
surface membrane receptors (Fu¨reder et al, 1995), response to activating
ligands, and distinct ultrastructural properties (Dvorak, 1991). A number
of studies suggest that MC heterogeneity is an organ-specific phenom-
enon. In particular, major differences were found when phenotypic
and functional properties were analyzed and compared in human
cutaneous and ‘‘noncutaneous’’ MC. Specifically, cutaneous MC, but
not lung MC, express large amounts of the mast cell specific enzyme
chymase (Irani et al, 1986). Furthermore, juvenile foreskin MC release
their mediators in response to C5a, morphine, and substance-P, whereas
lung MC were found to be unresponsive against these agonists (Benyon
et al, 1987; Lawrence et al, 1987; Fu¨reder et al, 1995). We have recently
described that MC derived from human foreskin, as opposed to lung
or other visceral organs, express CD88, the receptor for the complement
activation product C5a (Fu¨reder et al, 1995). These observations
prompted us to look for additional biologic and antigenic differences
between cutaneous and ‘‘noncutaneous’’ MC. For this purpose, we
isolated human MC from juvenile foreskin, adult mammary skin, and
lung tissue specimens, and analyzed the immunophenotypic and
functional properties of these cells.
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CD R MoAb class MC MC HMC-1
025 IL-2Rα BC96 IgG1 – – –/1
040 CD40LR G28–5 IgG1 – – 11
095 APO1/FAS 7C11 IgM – – 1
105 TGFβR F430C-5 IgG1 – – –
114 G-CSFR 129 IgG1 – – –
116 GM-CSFRα hGM-CSFR-M1 IgG1 – – 1
117 SCFR/c-kit YB5.B8 IgG1 11 11 11
118 IFNRα/β IFNαR3 IgG1 – – –/1
121a IL-1RI hIL-1R1-M1 IgG1 – – –
121a IL-1RI M10 IgG1 – – –
121b IL-1RII 1H7 IgG2b – – –/1
122 IL-2Rβ Mikβ1 IgG2a – – –/1
123 IL-3Rα 9F5 IgG1 – – –
126 IL-6Rα B-C22 IgG1 – – –
127 IL-7R αIL-7R IgG – – –
w128 IL-8R B-F25 IgM – – –
130 gp130 AM64 IgG – – 1
w131 β to IL-3/5R 3D7 IgG1 – – –
132 γ to IL-2/4/7/9R AG43C IgG1 – – –
134 OX40 L106 IgG1 – – –
135 FLT3 4G8 IgG1 – – –
w136 MSP-R ID1 IgG2a – –/1 –
w137 4–1BB 4B4 IgG1 – – –
140a PDGF-RA PR292 IgG1 – – –
140b PDGF-RB PR7212 IgG1 – – –
aForeskin and lung MC were purified and prepared as described in the text. A combined
toluidine blue/immunofluorescence staining technique was applied to determine the
reactivity of primary MC with MoAb. At least three MC preparations (three different
donors) were analyzed for each individual MoAb. HMC-1 cells were analyzed by flow
cytometry. The results are expressed as percentage reactive cells using a score system: 11,
more than 90% of cells reactive; 1, 50%–90% of cells reactive; 1/–, 20%–49% of cells
reactive; –/1 , 10%–19% of the cells reactive; –, less than 10% of cells reactive. Results
obtained with lung MC and HMC-1 (CD25–130) were found to correspond to our
previous data (Agis et al, 1996).
MATERIALS AND METHODS
Monoclonal antibodies (MoAb) A number of MoAb were used to immun-
ophenotype MC. One part of MoAb were obtained from the IVth (Vienna
1989), Vth (Boston 1993), or VIth (Kobe 1996) International Workshops and
Conferences on Human Leukocyte Differentiation Antigens. A specification of
MoAb (CD, Ig subclass) is provided in Tables I–VIII. The following MoAb
were purchased: A2MRα-2 and A2MRβ-1 (both CD91) from American
Diagnostica (Greenwich, CT); S-HCL3 (CD11c), L138 (CD13), and L60
(CD43) from Becton Dickinson (San Jose, CA); and HD39 (CD22) from
Behring (Marburg, Germany). The MoAb VNR147 (CD51), W-CAM-1
(CD54), G3 (anti-tryptase), B7 (anti-chymase), and human myeloma IgE were
from Chemicon (Temecula, CA); F10–44–2 (CD44) was from Cymbus
Bioscience (Southampton, U.K.); and MoAb 366 (CD13) was from Coulter
Clone (Hialeah, FL). The MoAb JC/70A (CD31), PD7/26 1 2B11 (CD45),
PG-M1 (CD68R), and F8/86 (against von Willebrand factor, vWF) were
purchased from Dako (Glostrup, Denmark); MoAb M10 (CD121a) and 1H7
(CD121b) were from Genzyme (Cambridge, MA); and BL4 (CD4), BEAR 1
(CD11b), K20 (CD29), 2E1 (CD32), QBEND10 (CD34), SZ2 (CD42b), J4–
48 (CD46), J4.57 (CD48), HP2B6 (CD49a), HP2/1 (CD49d), AMF7 (CD51),
84H10 (CD54), and E124.2.8 (anti-IgE) were from Immunotech (Marseilles,
France). The MoAb MEM-102 (CD48) was from Monosan (Uden,
Netherlands), and WM15 (CD13), 2F3 (CD15s), 2H5 (CD15s), HIB22 (CD22),
FLI8.26 (CD32), M-B371 (CD37), HIT2 (CD38), GoH3 (CD49f), IA10
(CD55), H19 (CD59), 68–5H11 (CD62E), DREG-56 (CD62L), JS-81 (CD81),
A59 (CD89), and 9F5 (anti-IL-3Rα/CD123) were from Pharmingen (San
Diego, CA). A MoAb against GM-CSFRα (CD116) was from Santa Cruz
Biotechnology (Santa Cruz, CA), the anti-C5aR MoAb S5/1 and W17/1
(CD88) were from Serotec (Oxford, U.K.), and MoAb RFB4 (CD22) was
from Southern Biotechnology (Birmingham, AL). The MoAb LAM-89 (anti-
laminin) and BA-4 (anti-elastin) were purchased from Sigma (St. Louis, MO).
The anti-c-kit MoAb YB5.B8 (CD117) was kindly provided by Dr. L.K.
Table II. Reactivity of mast cells with MoAb to integrinsa
Reactivity of MoAb with
CD integrin MoAb Ig-class Skin MC Lung MC HMC-1
β1
29 β chain K20 IgG2a 11 11 11
49a VLA-1α HP2B6 IgG1 – – 1/–
49b VLA-2α 6F1 IgG1 – – –/1
49d VLA-4α HP2/1 IgG1 1/– 1 1
49f VLA-6α GoH3 IgG2aκ – – –
β2
11a LFA-1α 25–3-1 IgG1 – – –
11a LFA-1α MHM24 IgG1 – – –
11b C3biR VIM-12 IgG1 – – –
11b C3biR BEAR 1 IgG1κ – – –
11c CR4 3.9 IgG1 – – –
11c CR4 S-HCL3 IgG2b – – –
18 β chain MHM23 IgG1 – – –
β3
41 αIIb PL1.64 IgG1 – – –
51 VNRα 13C2 IgG1 1 1 –/1
51 VNRα AMF7 IgG1 1/– 1 1/–
61 VNRβ SZ.21 IgG1 1/– 1/– 1/–
61 VNRβ Y – 2/51 IgG1κ 1/– –/1 –/1
β4
104 β4-chain 439–9B IgG2b – – –
β7
n.c. β7-chain F1B21 IgG2a – – –
n.c. β7-chain F1B30 IgG2a – – –
n.c. β7-chain F1B504 IgG2a – – –
103 HML-1α HML-1 IgG2a – – –
aForeskin MC and lung MC were enriched and analyzed as described in the text. For
the score of antibody reactivity see the footnote to Table I. Results obtained with lung
MC and HMC-1 were found to correspond to our previous data (Agis et al, 1996). VNR,
vitronectin receptor.
Table III. Reactivity of mast cells with MoAb to Ig-
superfamily type recognition receptors
Reactivity of MoAb with
CD antigen MoAb Ig-class Skin MC Lung MC HMC-1
02 LFA-2 O275 IgG1 – – 1/–
28 B7-ligand KOLT2 IgG1 – – –
31 PECAM-1 SG134 IgG – – –
31 PECAM-1 5 A2.G5 IgG1 – – –
54 ICAM-1 RR1/1 IgG1 1 1/– 1
54 ICAM-1 84H10 IgG1 1/– 1 11
56 N-CAM Leu19 IgG1 – – –
58 LFA-3 TS2/9 IgG1 1 11 11
80 BB1/B7 BB1 IgM – – –
102 ICAM-2 CBR-IC2/1 IgG2aκ – –/1 –
102 ICAM-2 CBR-IC2/2 IgG2aκ 1/– –/1 –
106 VCAM-1 2G7 IgG1 – – –
aFor score and specifications see the footnotes to Tables I and II. Results obtained with
lung MC and HMC-1 were found to correspond to our previous data (Agis et al, 1996).
Ashman (University of Adelaide, Australia), and MoAb 1A2.C5 (CD117) was
kindly sent by Dr. H.J. Bu¨hring (University of Tu¨bingen, Germany).
Other reagents and buffers Collagenase type II was purchased from Sebak
(Suben, Austria), fetal calf serum was from Hyclone (Logan, Utah), and L-
glutamine, penicillin/streptomycin, gentamycin, and fungizone were from
Gibco Life Technologies (Gaithersburg, MD). Recombinant human (rh) SCF,
as well as rhIL-1, rhIL-2, rhIL-4 through rhIL-11, rhIL-13, and rhIL-15 were
from Peprotech (Rocky Hill, NY), rhIL-3 was from Sandoz (Vienna, Austria),
rhIL-12 was from R&D Systems (Minneapolis, MN), rhC5a, toluidine blue,
protease type XXIV, and 3-amino-9-ethylcarbazole were from Sigma, and
tris-(hydroxymethyl)-aminomethan was from Biomol (Hamburg, Germany).
Fluorescein isothiocyanate-goat F(ab9)2 anti-mouse IgG and fluorescein iso-
thiocyanate-goat anti-rat IgG were from Caltag Laboratories (San Francisco,
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Table IV. CD50 (ICAM-3) expression on MC derived from
juvenile foreskin and other tissuesa
Reactivity of MoAb with
Skin MC Skin MC Lung HMC-1
CD R MoAb Ig-class (foreskin) (adult skin) MC
50 ICAM-3 CBR-IC3/1 IgG1κ – n.t. 1 11
50 ICAM-3 BU68 IgG1 – – 1 11
50 ICAM-3 186–2G9 IgG2b – – 1 11
50 ICAM-3 B-N2 IgG – – 1 11
50 ICAM-3 B-P12 IgG – – 1 11
50 ICAM-3 B-R1 IgG – – 1/– 11
50 ICAM-3 AZN-ICM3.1 IgG1κ – – –/1 11
aForeskin MC, adult mammary skin MC, and lung MC were enriched and analyzed by
MoAb as described in the text. HMC-1 cells were analyzed by flow cytometry. For
definitions and score of antibody reactivity see the footnote to Table I.
Table V. Reactivity of mast cells with MoAb to other
adhesion receptors and related moleclusa
Reactivity of MoAb with
CD R MoAb Ig-class Skin MC Lung MC HMC-1
04 T4/Cl-IIR BL4 IgG2a – – –
08 T8/Cl-IR BB29 IgM – – –
09 p24 MM2/57 IgG2b 11 11 11
15 3-FAL PM-81 IgM – – –
15s sLex 2F3 IgMκ – – –
15s sLex 2H5 IgMκ – – –
30 Ki-1 AC10 IgG2b – – –
36 TSP-R ESIVC7 IgG1 – – –
42a GPIX/gp53 Beb1 IgG1 – – –
43 Leukosialin L10 IgG1 11 11 11
44 Pgp-1 A3D8 IgG1 11 11 11
62E E-selectin 68–5H11 IgG1κ – – –
62L L-selectin DREG-56 IgG1κ – – –
62P P-selectin G1 IgG1 – – –
86 B7–2 FUN-1 IgG1 – – –
138 syndecan 1 MI15 IgG1 – – –
144 VE-cadherin 55–7H1 IgG1κ – – –
146 MUC-18 OJ79 IgG1 – – –
147 Neurothelin UM-8D6 IgG3 1/– –/1 11
147 Neurothelin H84 IgG2b 1 1/– 11
147 Neurothelin HI197 IgG1 –/1 –/1 11
147 Neurothelin HIM6 IgG1 –/1 –/1 11
151 PETA-3 11B1.G4 IgG2a 11 11 11
151 PETA-3 14A2.H1 IgG1 1 1 11
153 CD30L M81 IgG2b – – –
154 CD40L 5C8 IgG2a – – –
162 PSGL-1 PL1 IgG1κ – – 1/–
164 MGC-24 105A5 IgG3 – – 1
165 gp37 AD2 IgG1 – – 1
166 ALCAM-1 3A6 IgG1 – – –
aFor definitions and score of antibody reactivity see the footnote to Table I.
Table VI. Reactivity of mast cells with MoAb against
immunoglobulin receptorsa
Reactivity of MoAb with
CD Fc-receptor MoAb Ig class Skin MC Lung MC HMC-1
CD89 FcαR A59 IgG1 – – –
CD23 FcεRII MHM6 IgG1 – – –
CD64 FcγRI 22.2 IgG1 – – –/1
CD32 FcγRII IV.3 IgG2b 1 – 11
CD32 FcγRII FLI8.26 IgG2bκ 1 – 11
CD32 FcγRII 2E1 IgG2a 1 – 11
CD16 FcγRIII 3G8 IgG1 – – –
aFor definitions and score of antibody reactivity see the footnote to Table I. Results
obtained with lung MC and HMC-1 were found to correspond to our previous data (Agis
et al, 1996).
CA) and human AB-serum from Sera Lab (Crawley Down, U.K.). Biotinylated
horse anti-mouse IgG and avidin-biotin-peroxidase complex (ABC Elite kit)
were from Vector Laboratories (Burlingame, CA). Biotinylated goat anti-mouse
immunoglobulin and peroxidase conjugated streptavidin were purchased from
Biogenex Laboratories (San Ramon, CA). Histamine release buffer (Immuno-
tech) contained 20 mM PIPES, glucose (1 g per liter), and 1 mM CaCl2. One
litre of Mg/Ca-free Tyrode’s buffer contained 0.2 g KCl, 0.05 g NaH2
PO4.H2O, 8.0 g NaCl, and 1 g glucose. Iscove’s modified Dulbecco’s medium
was purchased from Gibco Life Technologies and RPMI 1640 medium from
PAA Laboratories (Linz, Austria).
Preparation and culture of mast cells Foreskin was obtained from 55
children (age 2 mo to 16 y; median, 4 y; mean, 5 y) undergoing circumcision.
Informed consent was obtained from parents in each case. Normal mammary
skin was obtained from five adult females who underwent reduction surgery
after informed consent was obtained. Resected skin specimens were transported
to the laboratory immediately after resection. Cutaneous MC were isolated
according to standard procedures (Fu¨reder et al, 1995). In brief, tissue was cut
into small pieces and washed in Tyrode’s buffer. Tissue fragments were incubated
in collagenase type II (2 mg per ml) for 90–180 min at 37°C. After digestion,
cells were recovered, washed, and examined for MC by toluidine blue staining.
Isolated foreskin MC were cultured in RPMI 1640 medium supplemented
with 10% fetal calf serum at 37°C for at least 12 h before being used in
immunostaining or release experiments. Human lung MC were enriched from
lung tissue obtained from patients with bronchiogenic carcinoma (n 5 24, after
informed consent) using collagenase type II as described (Schulman et al, 1982;
Valent et al, 1989a). The human mast cell line HMC-1 was kindly provided by
Dr. J.H. Butterfield (Mayo Clinic, Rochester, MN). HMC-1 cells were
maintained in Iscove’s modified Dulbecco’s medium with 10% fetal calf serum
and antibiotics at 37°C/5% CO2.
Evaluation of surface antigen expression Expression of cell surface antigens
on primary MC was analyzed by combined toluidine blue/immunofluorescence
staining (Valent et al, 1989a). In brief, cells were preincubated in AB serum for
30 min, incubated with MoAb for 30 min (4°C), washed, and then exposed
to second-step fluorescein-labeled goat F(ab9)2 IgG anti-mouse antibody for
another 30 min (4°C). Cells were then fixed in 0.025% glutaraldehyde for
1 min, washed, and incubated with toluidine blue (0.0125%) for 8 min.
After washing, cells were examined under bright-field and fluorescence-light
(fluorescence microscope, Olympus, Vienna, Austria). At least 20 cells were
analyzed for each individual MoAb. Antigen expression on HMC-1 cells was
analyzed by flow cytometry on a FACScan (Becton Dickinson, Palo Alto, CA)
as described (Agis et al, 1996). All MoAb used were checked for cell reactivity
and specificity during the VIth International Workshop and Conference on
Human Leukocyte Differentiation Antigens (Kobe, 1996).
In situ staining experiments Immunohistochemistry on paraffin-embedded
tissue (juvenile foreskin, n 5 1) was performed as described previously (Hsu
et al, 1981). In brief, paraffin-embedded specimens were cut into 2 µm thin
(serial) sections and mounted on silan-coated slides. Then, sections were
dewaxed in xylol. For several antigens, the antigenicity was enhanced either by
pretreating the sections with 0.05% protease type XXIV, or by high temperature
antigen unmasking using a microwave oven as described (Shi et al, 1991;
Cattoretti et al, 1993). Protease digestion was performed in case of staining for
CD31 (JC/70A), CD51 (VNR147), CD54 (W-CAM-1), CD68R (PG-M1),
CD117 (1A2.C5), vWF (F8/86), chymase (B7), laminin (LAM-89), and elastin
(BA-4). Microwave oven heating was applied in case of staining for CD34
(QBEND10) and CD44 (F10–44–2). In case of staining for CD43 (L60), CD45
(PD7/26 1 2B11), and tryptase (G3), sections were not pretreated. After each
step, the sections were rinsed twice in 0.05 M Tris-buffered saline (pH 7.5).
Sections were incubated with ‘‘first-step’’ MoAb at room temperature for 1 h,
incubated with biotinylated ‘‘second-step’’ antibodies for 30 min at room
temperature, and then incubated with avidin-biotin-peroxidase complex or
peroxidase-conjugated streptavidin for 30 min at room temperature. Bound
antibody was visualized with 3-amino-9-ethylcarbazole for 5–10 min. Slides
were counter-stained with Mayer’s Haemalaun for 3 min.
Histamine release experiments Histamine release was performed on skin
MC (foreskin, n 5 11; adult skin, n 5 2) according to published techniques
(Valent et al, 1989b). In case of IgE-dependent release, skin MC were
preincubated with IgE (myeloma derived) for 3 h at 4°C, washed, and
resuspended in histamine release buffer. Then, skin MC were exposed to anti-
IgE MoAb E124.2.8 (0.01–10 µg per ml) for 30–45 min. Skin MC were also
exposed to rhSCF (0.01–100 ng per ml), rhIL-1–4 (100 U per ml), rhIL-5–13,
and rhIL-15 (each 100 ng per ml), or rhC5a (10–1000 ng per ml). Cytokines
were added to MC for either 45 min (n 5 4) or 90 min (n 5 2) in 96 well
microtiter plates (Costar, Cambridge, MA) at 37°C. The ‘‘priming-effect’’ of
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Table VII. Overview of reactivity of foreskin MC with MoAb: comparison with other MCa
Skin MC 11 009, 029, 043, 044, 045RB, 046, 047, 055, 059, 060, 063, 082, 092, 097, 099, 117, w149, 151
1 032, 033, 045, 051, 053, 054, 058, 081, 084, 088, 098, 157
1/– 048, 049d, 061, 102, 147
–/1 083, 087
– 01a, 01b, 01c, 002, 003, 004, 005, 006, 007, 008, 010, 011a, 011b, 011c, 012, 014, 015, 015s, 016, 017, 018, 019, 020, 021, 023, 024, 025,
027, 028, 030, 031, 034, 035, 036, 037, 038, 039, 040, 041, 042a, 045RO, 049a, 049b, 049f, 050, 052, 056, 062E, 062L, 062P, 064, 065,
066, 067, 068, 069, 070, 071, 072, 073, 074, 075, 076, 077, 078, 079, 080, 085, 086, 089, 090, 091, 093, 094, 095, 096, 101, 103, 104, 105,
106, 108, 114, 115, 116, 118, 121a, 121b, 122, 123, 126, 127, w128, 130, 131, 132, 134, 135, w136, w137, 138, 139, 140a, 140b, 141, 142,
143, 144, w145, 146, 148, w150, 152, 153, 154, 155, 156, 162, 164, 165, 166
Lung MC 11 009, 029, 043, 044, 046, 047, 048, 053, 055, 058, 059, 063, 081, 082, 084, 092, 097, 098, 099, 117, w149, 151
1 033, 049d, 050, 051, 054, 157, 163
1/– 060, 061, 069, 087, 090, 107b, 147
–/1 052, 093, 102, 108, 124, w136
– 001a, 001b, 001c, 002, 003, 004, 005, 006, 007, 008, 010, 011a, 011b, 011c, 014, 015, 015s, 016, 017, 018, 019, 020, 021, 023, 024, 025,
027, 028, 030, 031, 032, 034, 035, 036, 037, 038, 039, 040, 041, 042a, 049a, 049b, 049f, 056, 057, 062E, 062L, 062P, 064, 065, 066, 066b,
068, 070, 071, 072, 073, 074, 075, 076, 077, 078, 079b, 080, 083, 085, 086, 088, 089, 091, 094, 095, 096, 101, 103, 104, 105, 106, 114,
116, 118, 120a, 120b, 121a, 121b, 122, 123, 126, 127, w128, 130, 131, 132, 134, 135, w137, 138, 139, 140a, 140b, 141, 142, 143, 144,
w145, 146, 148, w150, 152, 153, 154, 155, 156, 162, 164, 165, 166
HMC-1 11 009, 013, 029, 032, 037, 040, 043, 044, 046, 047, 048, 050, 053, 054, 055, 058, 059, 063, 066, 081, 082, 084, 087, 092, 097, 098, 099, 117,
147, w149, 151, 155
1 033, 049d, 072, 088, 095, 116, 130, 164, 165
1/– 002, 049a, 051, 052, 061, 071, 101, 108, 118, 157, 162
–/1 025, 049b, 060, 064, 118, 120a, 120b, 121b, 122, 152
- 001a, 001b, 001c, 002R, 003, 004, 005, 006, 007, 008, 010, 011a, 011b, 011c, 012, 014, 015, 015s, 016, 017, 018, 019, 020, 021, 023, 024,
027, 028, 030, 031, 034, 035, 036, 038, 039, 041, 042a, 049f, 056, 062E, 062L, 062P, 065, 066b, 068, 069, 070, 073, 074, 075, 076, 077,
078, 079b, 080, 083, 085, 086, 089, 090, 091, 093, 094, 096, 102, 103, 104, 105, 106, 114, 121a, 123, 124, 126, 127, w128, 131, 132, 134,
135, w136, w137, 138, 139, 140a, 140b, 141, 142, 143, 144, w145, 146, 148, w150, 153, 154, 156, 163, 166
aFor definitions and score of antibody reactivity see the footnote to Table I. Results obtained with lung MC and HMC-1 correspond to our previous data
(Fu¨reder et al, 1995; Agis et al, 1996).
Table VIII. Reactivity of antibodies on paraffin embedded
juvenile foreskina
Reactivity
CD Antigen Clone Ig-class of MC Reference cells
31 PECAM-1 JC/70A IgG1 – endothelial cells
34 HPCA-1 QBEND10 IgG1 – endothelial cells
43 leukosialin L60 IgG1 1 lymphocytes
44 HCAM F10–44–2 IgG2a 1 lymphocyte
45 LCA PD7/26 1 2B11 IgG1 1 lymphocytes
51 integrin αV VNR147 IgG1 1 osteoclastsb
54 ICAM-1 W-CAM-1 IgG 1 keratinocytes
68R macrosialin PG-M1 IgG3 1 macrophages
117 SCF-R 1 A2.C5 IgG3 1 mast cells
n.c. α-vWF F8/86 IgG1 – endothelial cells
n.c. MC-tryptase G3 IgG1 1 mast cells
n.c. MC-chymase B7 IgG1 1 mast cells
n.c. laminin LAM-89 IgG1 – vessel wall cells
n.c. elastin BA-4 IgG1 – vessel wall cells
aIn situ detection of antigens in sections of paraffin embedded foreskin. The applied
immunohistochemistry technique is described in the text. The applicability in paraffin
embedded sections and the specificity of the MoAb were tested by evaluating their
reactivity with reference cells known to express the respective antigen.
bIn the case of CD51, a bone marrow section was used to control reactivity with
reference cells.
the cytokines on IgE-dependent mediator release of MC (foreskin) was also
analyzed. For this purpose, MC were first exposed to IgE (see above), then to
rhSCF (100 ng per ml), rhIL-9–13 (100 ng per ml each), rhIL-15 (100 ng per
ml), or control medium for 15 min at 37°C, and then stimulated with various
concentrations of anti-IgE MoAb E124.2.8 (0.1–10 µg per ml) for 30 min.
After incubation with agonists, cells were centrifuged at 4°C and the cell-free
supernatants recovered by aspiration. Liberated histamine was measured by a
commercial radioimmunoassay (Immunotech). Total histamine in cell suspen-
sions was quantitated after cell lysis in distilled water and freeze thawing.
Histamine release was expressed as percentage of total histamine.
RESULTS
Sufficient amounts of MC are detectable in tissue
dispersates Mast cells were isolated from juvenile foreskin (n 5 55),
adult mammary skin (n 5 5), and lung (n 5 24) by incubation in
collagenase. As determined by toluidine blue staining of cytospin
preparations, the percentage of MC in the primary foreskin cell
suspensions ranged between 1% and 9%, between 0.5% and 3% in
adult mammary skin cell suspensions, and between 1% and 16% in the
lung cell suspension. Based on their morphology, the isolated cutaneous
MC appeared to have good viability. In line with their ‘‘viable’’
morphology, the skin MC showed a low baseline level of spontaneous
histamine release (mean 6 SD, 2.8 6 1.8%; range, 0.8%–6.8%, n 5 11).
Cutaneous MC express c-kit Expression of cytokine R on skin
MC was analyzed by using MoAb directed against previously or more
recently clustered antigens. Like MC from human lung, cutaneous
MC (from foreskin and adult skin) were found to react with MoAb
to stem cell factor receptor c-kit (CD117). In contrast, foreskin MC
did not react with MoAb to other cytokine R, including IL-3Rα
(CD123), GM-CSFRα (CD116), and G-CSFR (CD114) (Table I).
No difference was found when the cytokine receptor profile of skin
MC was compared with the well-established phenotype of lung MC.
Table I shows a summary of staining results obtained with MoAb
against cytokine receptors.
Skin MC express a unique profile of adhesion receptors (R) The
distribution and function of various cells in the tissues supposedly is
associated with expression of distinct adhesion receptors. In this study,
the adhesion receptor profile of skin MC was established and compared
with the R profile of lung MC and HMC-1. Adhesion R detectable
on foreskin MC were CD29 (common β-chain of β1 integrins),
CD49d (VLA-4α), CD51 (vitronectin-R[VNR]-α), and CD61
(VNRβ) (Table II). Moreover, foreskin MC were found to react with
MoAb against CD54 (ICAM-1), CD9 (p24), CD43 (leukosialin,
ICAM-1-ligand), CD44 (Pgp-1, hyaluronate-R), and CD58 (LFA-3)
(Tables III–V). Novel adhesion-related CD antigens detectable on
MC were CD147 (neurothelin) and CD151 (PETA-3) (Table V).
The ICAM-3 antigen (CD50) that is expressed on lung MC and MC
from other visceral organs (Agis et al, 1996) was not detectable on
foreskin MC or MC of adult mammary skin (Table IV). Thus, using
seven different MoAb against ICAM-3, we were not able to obtain a
staining signal with foreskin MC or MC of adult mammary skin in
our toluidine blue/immunofluorescence double staining technique,
whereas the same CD50 clones produced a significant reactivity with
lung MC in parallel experiments (Table IV). The HMC-1 cell line
was also found to react with CD50 MoAb (Table IV). A number of
VOL. 111, NO. 4 OCTOBER 1998 IMMUNOPHENOTYPE OF SKIN MAST CELLS 693
adhesion receptors were neither detected on cutaneous MC nor
detected on lung MC (Tables II–V). Overall, cutaneous MC express
a similar, but not identical profile of surface adhesion receptors when
compared with lung MC. In contrast to lung MC, skin MC do not
express significant amounts of ICAM-3.
Cutaneous MC express FceRI and FcgRII Basophils and mast
cells reportedly express high affinity IgE binding sites on their surface;
however, these cells may express additional Ig-binding sites as well. In
this study, human skin MC (foreskin and adult skin) were found to
react with three different MoAb directed against the FcγRII (CD32),
namely IV.3, 2E1, and FLI8.26. In contrast to MC from foreskin or
adult skin, lung MC did not react with MoAb against FcγRII. Neither
skin MC nor lung MC were found to react with MoAb against FcαR
(CD89), FcεRII (CD23), FcγRI (CD64), or FcγRIII (CD16). Table VI
shows a summary of staining results obtained with MoAb against
Ig receptors.
Skin MC express various complement and virus receptors A
number of recently defined CD antigens have been identified as
binding sites for both complement-related and viral antigen. Likewise,
the membrane cofactor protein CD46 has recently been identified as
a receptor (R) for the measles virus. In line with our previous
observations (Fu¨reder et al, 1995), foreskin MC were found to express
membrane cofactor protein CD46 and the decay-accelerating factor,
an echovirus receptor. Moreover, foreskin MC were found to react
with MoAb against the membrane attack complex inhibitory factor.
The ICAM-1 antigen CD54, a well-known rhinovirus receptor, is
also expressed on cutaneous MC. Cutaneous MC did not react with
MoAb against CD4 (HIV-R), CD21 (EBV-R 5 CR2), CD49b (echo-
V-1-R), CD50 (ICAM-3 5 HIV-1-R), or CD155 (polio-V-R).
Foreskin MC were also found to lack significant amounts of CR1
(CD35), CR3 (CD11b), and CR4 (CD11c).
In line with our previous data (Fu¨reder et al, 1995), MoAb against
the C5aR (CD88) were found to react with MC from human juvenile
foreskin. By contrast, these MoAb did not stain human MC derived
from adult mammary skin. Thus, the C5aR is differentially expressed
on various MC populations, but does not indicate organ-specific
heterogeneity of MC.
Cutaneous MC express distinct novel CD antigens Novel CD
antigens detectable on foreskin MC (and lung MC) were CD147
(neurothelin), the platelet-endothelial cell tetraspan antigen-3 (PETA-
3 5 CD151), CDw149 (MEM-133), and CD157 (BST-1 5 bone
marrow stromal cell antigen-1). In addition, foreskin MC were
found to react with MoAb against members of the transmembrane 4
superfamily, namely CD53 (gp32–40), CD63 (ME491), and CD81
(TAPA-1), which are all involved in cellular signalling. A summary of
surface staining results obtained with all MoAb is depicted in Table VII.
Cutaneous MC express CD antigens in situ To confirm expression
of CD antigens in cutaneous MC in situ staining was performed using
human juvenile foreskin. The experiments were performed using
serial sections stained with anti-tryptase versus other MoAb. In these
experiments most cutaneous (tryptase1) MC stained positive for
chymase (MCTC). Moreover, cutaneous tryptase
1 MC were recognized
by MoAb to c-kit, CD43, CD44, CD45, CD51, CD54, and CD68R.
No reactivity of MC with MoAb against CD31, CD34, vWF,
or laminin was found. Table VIII shows a summary of in situ
staining results.
Cutaneous MC are responsive against distinct agonists In order
to determine the functional significance of surface receptor expression
on skin MC, histamine release experiments were performed. Incubation
of foreskin MC with c-kit ligand rhSCF for 45 min was followed by
specific mediator secretion in three of 10 donors. In these three
responsive donors, rhSCF (100 ng per ml) raised the amount of
liberated histamine from 0.8% (spontaneous release) to 9.6%, from
1.6% to 11.8%, and from 2.8% to 23.5%. In the other donors, no
measurable release was elicited by rhSCF. In all donors examined,
incubation of MC with anti-IgE resulted in substantial increase of
histamine release above control [anti-IgE, 1 µg per ml, 20.3 6 8.8%
Figure 1. Effect of SCF preincubation on IgE-dependent release of
histamine in foreskin MC. Enriched foreskin MC were exposed to rhSCF
(100 ng per ml) (d) or control medium (j) for 15 min and thereafter to anti-
IgE antibody E124.2.8 for 30 min at 37°C. Histamine release is expressed as
percentage of total histamine. The results represent the mean of duplicates
obtained in one donor. Similar results were obtained in two other donors.
versus control, 2.6 6 1.5% (mean 6 SD, n 5 3)]. Preincubation of
foreskin MC with rhSCF for 15 min prior to anti-IgE activation
(30 min) resulted in an enhanced liberation of histamine when
compared with preincubation in control medium (Fig 1). The other
cytokines (IL-9, IL-10, IL-11, IL-12, IL-13, IL-15) did not modulate
the releasability of MC. Moreover, none of the cytokines tested except
SCF, induced histamine release from MC in the absence of anti-IgE.
According to previous observations, rhC5a induced concentration-
dependent secretion of histamine from juvenile foreskin MC [rhC5a,
1000 ng per ml, 90 min, 11.5 6 6.7% versus control, 1.7 6 1.0%
(mean 6 SD, n 5 3)]. By contrast, rhC5a did not induce histamine
release from mammary skin MC (n 5 3) above control (not shown).
DISCUSSION
Mast cells are potent effector cells of the immune system. These cells
express a number of inflammatory mediators in their granules and can
release their products upon stimulation by IgE-dependent or IgE-
independent stimuli. Depending on the tissue environment and condi-
tion, MC express distinct patterns of surface receptors for various active
ligands. In this study we have determined the receptor profile of
human cutaneous MC. The results of our study show that cutaneous
MC differ from other MC by expressing substantial amounts of FcγRII,
and by lack of detectable ICAM-3/CD50. Expression of the C5aR,
previously felt to be a marker of skin MC (indicating organ-specific
MC heterogeneity) was detectable on foreskin MC, but not on MC
isolated from adult mammary skin tissue or human lung.
Human MC reportedly express receptors for SCF, but do not
express significant amounts of other cytokine binding sites (Valent and
Bettelheim, 1992; Agis et al, 1996). In line with this notion, foreskin
MC were found to react with MoAb against c-kit, but did not react
with MoAb against a number of other cytokine receptors including
IL-3Rα, GM-CSFRα, G-CSFR, and IL-6R. Thus, human skin MC
express an identical cytokine receptor profile when compared with
other MC types. The failure of cutaneous MC to respond to cytokine
ligands other than SCF in our histamine release experiments is
compatible with this result. On the other hand, we cannot exclude
expression of very low amounts of interleukin receptors that could not
be detected by the staining technique applied. The possibility that the
isolation technique caused a loss of cytokine surface receptors could
be excluded, because other cells (non-MC-lineage cells) clearly reacted
with the respective MoAb in the same cell suspensions.
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An interesting observation was that cutaneous MC, but not lung
MC, react with MoAb against FcγRII (CD32). This Ig receptor has
been implicated in certain immune responses and has been detected
on human basophils (Stain et al, 1987) and mouse mast cell progenitors
(Daeron et al, 1992; Lantz and Huff, 1995). Furthermore, the FcγRII
has recently been localized on human uterine MC by Guo et al (1992).
In our previous studies, however, we were not able to localize the
FcγRII on MC (Valent et al, 1989a). This divergency may be explained
by the different MoAb used, differential expression of epitopes, or
different antibody titers. An alternative (more reasonable) explanation
seems to be MC heterogeneity. Another explanation for the differential
expression of the FcγRII on MC would be a different activation status
of MC, or a different expression of this receptor at various stages of
cell maturation. Interestingly, the immature MC line HMC-1 also
expressed FcγRII. An unresolved question is the functional role of the
FcγRII on human skin MC. One attractive hypothesis would be that
this binding site is involved in the regulation of mediator secretion, as
has been suggested for the basophil Fcγ receptor.
Mast cells express a characteristic profile of adhesion receptors (Valent
and Bettelheim, 1992; Agis et al, 1996). In particular, lung MC express
CD29 (β chain of β1 integrins), CD49d (VLA4α), CD54 (ICAM-1),
CD51 (VNRα), and CD61 (VNRβ) (Valent and Bettelheim, 1992;
Agis et al, 1996). The ICAM-3 antigen (CD50) has also been detected
on human lung MC (Agis et al, 1996). By contrast, however, we were
not able to show a significant binding of CD50 MoAb to MC derived
from juvenile foreskin or adult mammary skin in this study. These
observations suggest that, in contrast to lung MC, skin MC lack (or
express only very low amounts of) CD50. The functional significance
of this organ-specific heterogeneity of MC is not known. The other
adhesion receptors analyzed showed an identical cellular distribution
when lung MC and skin MC were compared with each other.
In order to confirm expression of antigens in skin MC, in situ
staining experiments were performed. In these experiments we were
able to show in situ expression of CD43, CD44, CD45, CD51, CD54,
and CD117 (c-kit) in cutaneous MC. These results are in line with
our earlier experiments performed on cardiac MC (Sperr et al, 1994;
Bankl et al, 1995). The MC enzymes tryptase and chymase were also
detectable in foreskin MC. Thus, corresponding to previous findings
(Irani et al, 1986) the vast majority of cutaneous MC were found to
coexpress chymase and tryptase (MCTC). Only few MC appeared to
express tryptase, but not chymase (MCT). MC expressing chymase but
not tryptase (MCC) were not detectable.
Recently a number of novel CD antigens have been defined, and
for several of these novel CD markers a specific functional role
has already been presented. Likewise, several novel adhesion related
molecules, like selectin ligands (such as PSGL-1/CD162), vascular
antigens, or cadherins, have been defined as CD molecules. So far,
however, little is known about the distribution of novel CD molecules
on human mast cells. The results of this study suggest that MC from
human foreskin (and lung) express the adhesion related molecules
CD147 (neurothelin) and CD151 (PETA-3), as well as CD149 and
CD157 (BST-1). Whether these novel CD antigens play a role in the
function, biology, or patho-physiology of human mast cell, remains to
be determined.
The C5a receptor reportedly is expressed on human foreskin MC,
but is not detectable on human lung MC (Fu¨reder et al, 1995). In this
study, we analyzed the expression of CD88 on MC derived from lung,
foreskin, and adult human mammary skin. As expected, foreskin MC
were recognized by MoAb against C5aR, whereas lung MC did not
react with CD88 MoAb. Unexpectedly, however, the C5aR was not
detectable on MC derived from adult human skin. This observation
argues against an organ-dependent distribution of this receptor on MC.
Rather it seems as if this antigen is differentially expressed on various
types of MC depending on the maturation stage or activation of cells.
In this regard it is noteworthy that synovial MC in patients with
rheumatoid arthritis, but not in osteoarthritis, express significant
amounts of C5aR (Kiener et al, 1998). Another important aspect is
that the HMC-1 cell line, which is immature and intrinsically activated
by a c-kit point mutation, expose substantial amounts of C5aR/CD88
(Fu¨reder et al, 1995). An alternative explanation for the differential
expression of C5aR on foreskin MC versus adult mammary MC could
be that cutaneous MC in different anatomical regions express different
phenotypes.
The C5a receptor (CD88) has been implicated in C5a-induced cell
migration and histamine release. In particular, we have recently shown
that the rhC5a-induced histamine release in foreskin MC is inhibitable
by preincubating the MC with a blocking CD88 MoAb (Fu¨reder et al,
1995). In this study, foreskin MC (expressing CD88) released histamine
in response to rhC5a, whereas lung MC and MC derived from adult
human mammary skin (both lacking CD88) did not release histamine
in response to rhC5a. These results support the hypothesis that the
effect of C5a on histamine release in MC is dependent on C5aR
expression.
A number of studies have shown that MC are responsive against
IgE-dependent stimuli and distinct cytokines. In our experiments, both
rhSCF and anti-IgE induced histamine release from human cutaneous
MC; however, whereas anti-IgE induced release of histamine in all
donors analyzed, rhSCF induced histamine release in a minority of the
patients only. This is in contrast to other human MC types (lung,
heart, uterus) that showed a clear (direct) response to SCF in all donors
tested (Sperr et al, 1993). Interestingly, a minor response of cutaneous
MC against SCF has also been described by Columbo et al (1992);
however, although rhSCF did not cause direct histamine secretion in
most donors, the cytokine was found to strongly upregulate the
responsiveness of MC against IgE-dependent cell activation in all MC
preparations. By contrast, the other cytokines tested neither induced
histamine release nor enhanced the IgE-dependent releasability of MC.
These observations are in line with previous studies on lung MC and
with the failure to detect significant amounts of cytokine receptors
(other than SCF receptor) on foreskin MC.
The exact pathophysiologic role of cutaneous MC in various skin
diseases is not completely understood; however, a number of potentially
important molecular and cellular interactions have been described and
some of the (novel) CD molecules may be of interest in this respect.
Likewise, several CD molecules have recently been identified as virus
binding sites. Specifically, CD46 is known as measles virus receptor
(Dorig et al, 1993), and CD54 as rhinovirus receptor (Staunton et al,
1989). The results of our studies suggest that human skin MC express
receptors for the measles virus (CD46), rhinovirus (CD54), echovirus
(CD55), and African swine fever virus (CD59). Whether these MC
binding sites are involved in the pathophysiology of infectious diseases
of the skin remains to be determined.
In summary, our data show that cutaneous MC express a similar
phenotype when compared with lung MC or other human MC types;
however, distinct surface antigens seem to be expressed differentially
on MC populations. Thus, in contrast to other MC, human skin MC
express large(r) amounts of FcγRII (CD32) and lack CD50. These
observations support the concept of human MC heterogeneity.
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